In recent years, as more and more biosimilars have been approved for marketing, “biosimilars” and “originator biologics” have gradually become hot topics of interest among patients. Especially in the treatment of cancer, autoimmune diseases, hematologic disorders, and ...Learn More

By:DengYue International Business Division Introduction: In the Era of Innovative Medicines, Why Are Patients Still Searching for Drugs?Over the past decade, China's innovative pharmaceutical industry has experienced unprecedented growth.From targeted therapies and PD-1/PD-L1 ...Learn More

In recent years, the restructuring of global pharmaceutical supply chains, strategic adjustments by multinational pharmaceutical companies, and the gradual expiration of drug patents have brought increasing attention to the stability of imported drug supplies. From rare disease ...Learn More

By:DengYue International Business Division In recent years, with increasing volatility in the global pharmaceutical supply chain, patients in China have frequently faced issues such as shortages of imported drugs, supply interruptions, and even market withdrawals. These ...Learn More

By:DengYue International Business Division Although individual rare diseases affect relatively small patient populations, their overall impact is far greater than many people realize. More than 7,000 rare diseases have been identified worldwide, collectively affecting an ...Learn More